Literature DB >> 11456048

Survival after induction chemotherapy and surgical resection for high-grade soft tissue sarcoma. Is radiation necessary?

R M Henshaw1, D A Priebat, D J Perry, B M Shmookler, M M Malawer.   

Abstract

BACKGROUND: Induction chemotherapy can produce dramatic necrosis in sarcomas-raising the question of whether or not radiation is necessary. This study reviews the clinical outcome of a subset of patients with high-grade extremity soft tissue sarcomas (STS) who were treated with induction chemotherapy and surgical resection but without radiation.
METHODS: Nonmetastatic, large, high-grade STS of the pelvis and extremities were treated with intra-arterial cisplatin, adriamycin, and, after 1995, ifosfamide. After induction, oncologic resection and histologic evaluation were performed. Good responders with good surgical margins were not treated with radiation.
RESULTS: Thirty-three patients, with a median follow-up of 5 years, were included. Limb salvage rate was 94%. Median tumor necrosis was 95%. Four patients developed metastatic disease with three subsequent deaths. Two local recurrences occurred; both patients were salvaged with reresection and adjuvant external beam radiotherapy, although one died of metastatic disease 10 years later. Relapse-free and overall survival is 80% and 88% at 5 and 10 years by Kaplan-Meier analysis.
CONCLUSIONS: Intensive induction chemotherapy can be extremely effective for high-grade STS, permitting limb-sparing surgery in lieu of amputation. Radiation may not be necessary if a good response to induction chemotherapy and negative wide margins are achieved. All patients with large, deep, high-grade STS of the extremities should be considered candidates for induction chemotherapy.

Entities:  

Mesh:

Year:  2001        PMID: 11456048     DOI: 10.1007/s10434-001-0484-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

Review 1.  Recent advances in radiotherapy for soft-tissue sarcoma.

Authors:  Brian O'Sullivan; Iain Ward; Charles Catton
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.075

2.  Local recurrence of disease after unplanned excisions of high-grade soft tissue sarcomas.

Authors:  Benjamin K Potter; Sheila C Adams; J David Pitcher; H Thomas Temple
Journal:  Clin Orthop Relat Res       Date:  2008-09-26       Impact factor: 4.176

3.  Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy.

Authors:  John T Mullen; Francis J Hornicek; David C Harmon; Kevin A Raskin; Yen-Lin Chen; Jackie Szymonifka; Beow Y Yeap; Edwin Choy; Thomas F DeLaney; G Petur Nielsen
Journal:  Cancer       Date:  2014-07-31       Impact factor: 6.860

4.  Neoadjuvant chemoradiation therapy for soft tissue sarcomas of the extremities.

Authors:  Samuel Aguiar Junior; Fábio de Oliveira Ferreira; Benedito Mauro Rossi; Erika Maria Monteiro Santos; João Victor Salvajoli; Ademar Lopes
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

5.  The role of irradiation in the management of locally recurrent non-metastatic soft tissue sarcoma of extremity/trunkal locations.

Authors:  James Fontanesi; Michael P Mott; David R Lucas; Peter R Miller; Michael J Kraut
Journal:  Sarcoma       Date:  2004

6.  Combination of Cisplatin, Ifosfamide, and Adriamycin as Neoadjuvant Chemotherapy for Extremity Soft Tissue Sarcoma: A Report of Twenty-Eight Patients.

Authors:  Bing Wang; Xiuchun Yu; Songfeng Xu; Ming Xu
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.889

7.  Standardization of evaluation method and prognostic significance of histological response to preoperative chemotherapy in high-grade non-round cell soft tissue sarcomas.

Authors:  Yoshinao Oda; Kazuhiro Tanaka; Takanori Hirose; Tadashi Hasegawa; Nobuyuki Hiruta; Masanori Hisaoka; Masato Yoshimoto; Hiroshi Otsuka; Hirofumi Bekki; Takeaki Ishii; Makoto Endo; Toshiyuki Kunisada; Toru Hiruma; Hiroyuki Tsuchiya; Hirohisa Katagiri; Yoshihiro Matsumoto; Akira Kawai; Robert Nakayama; Hiroyuki Kawashima; Satoshi Takenaka; Makoto Emori; Munenori Watanuki; Yukihiro Yoshida; Takeshi Okamoto; Junki Mizusawa; Haruhiko Fukuda; Toshifumi Ozaki; Yukihide Iwamoto; Takayuki Nojima
Journal:  BMC Cancer       Date:  2022-01-21       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.